14. Chronic inflammatory demyelinating polyneuropathy Clinical trials / Disease details
Clinical trials : 175 / Drugs : 161 - (DrugBank : 41) / Drug target genes : 13 - Drug target pathways : 24
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04480450 (ClinicalTrials.gov) | July 2023 | 16/7/2020 | Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy | Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy: A Phase II Study | Chronic Inflammatory Demyelinating Polyneuropathy | Drug: Rituximab | University of Kansas Medical Center | NULL | Not yet recruiting | 18 Years | N/A | All | 40 | Phase 2 | NULL |
| 2 | NCT04929236 (ClinicalTrials.gov) | January 1, 2023 | 11/6/2021 | Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients | Multicenter, Prospective, Double-Blinded, Parallel Group, Randomized Phase III Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients | Pediatric Chronic Inflammatory Demyelinating Polyneuropathy | Drug: Panzyga | Octapharma | NULL | Not yet recruiting | 2 Years | 17 Years | All | 30 | Phase 3 | NULL |
| 3 | NCT05581199 (ClinicalTrials.gov) | December 15, 2022 | 12/10/2022 | To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP | A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants With Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Chronic Inflammatory Demyelinating Polyneuropathy | Drug: Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly;Drug: Batoclimab 340 mg SC weekly;Drug: Placebo | Immunovant Sciences GmbH | NULL | Recruiting | 18 Years | N/A | All | 240 | Phase 2 | United States |
| 4 | NCT05584631 (ClinicalTrials.gov) | October 18, 2022 | 10/10/2022 | IVIG vs SCIG in CIDP | The Influence of Body Composition on Immunoglobulin Disposition After Intravenous and Subcutaneous Administration | CIDP;Immunoglobulin Deficiency;Chronic Inflammatory Demyelinating Polyneuropathy | Drug: Intravenous immune globulin G;Drug: Subcutaneous immune globulin G | Rutgers, The State University of New Jersey | NULL | Recruiting | 18 Years | 65 Years | All | 20 | Phase 1 | United States |
| 5 | NCT05327114 (ClinicalTrials.gov) | September 23, 2022 | 7/4/2022 | Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Phase 2/3, Multistage, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group Withdrawal Study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Drug: Nipocalimab;Drug: Placebo | Janssen Research & Development, LLC | NULL | Recruiting | 18 Years | N/A | All | 300 | Phase 2/Phase 3 | United States;Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Slovakia;Spain;Taiwan;United Kingdom;Romania;South Africa |
| 6 | NCT05084053 (ClinicalTrials.gov) | December 7, 2021 | 10/10/2021 | A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN) | A Phase 3 Study to Evaluate the Efficacy, Safety and Tolerability of TAK-771 for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN) in Japanese Subjects | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP);Multifocal Motor Neuropathy (MMN) | Drug: TAK-771 | Takeda | NULL | Recruiting | 18 Years | N/A | All | 21 | Phase 3 | Japan |
| 7 | NCT05014724 (ClinicalTrials.gov) | November 12, 2021 | 19/8/2021 | CIDP07 Rozanolixizumab Post Trial Access Program (the PTA) | CIDP07 Rozanolixizumab Post Trial Access Program (the PTA) | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Drug: Rozanolixizumab | UCB Biopharma SRL | NULL | Available | 18 Years | N/A | All | NULL | ||
| 8 | NCT04658472 (ClinicalTrials.gov) | April 28, 2021 | 1/12/2020 | Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | A Phase 2, Multicenter, Open-label, Non-randomized, Proof-of-concept Study Evaluating the Efficacy, Safety, and Tolerability of SAR445088 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Drug: SAR445088 (IV);Drug: SAR445088 (SC) | Bioverativ, a Sanofi company | NULL | Recruiting | 18 Years | N/A | All | 110 | Phase 2 | United States;Canada;China;France;Germany;Italy;Netherlands;Poland;Serbia;Spain |
| 9 | NCT04051944 (ClinicalTrials.gov) | August 21, 2019 | 8/8/2019 | A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy | An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Drug: Rozanolixizumab | UCB Biopharma SRL | NULL | Completed | 18 Years | N/A | All | 21 | Phase 2 | United States;Belgium;Denmark;France;Germany;Netherlands;Spain;United Kingdom |
| 10 | NCT03861481 (ClinicalTrials.gov) | March 26, 2019 | 1/3/2019 | A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy | A Multicenter, Randomized, Subject-Blind, Investigator-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Drug: Rozanolixizumab;Other: Placebo | UCB Biopharma S.P.R.L. | NULL | Completed | 18 Years | N/A | All | 34 | Phase 2 | United States;Belgium;Denmark;France;Germany;Netherlands;Spain;United Kingdom;Canada |
| 11 | NCT03801135 (ClinicalTrials.gov) | October 3, 2018 | 4/10/2018 | Changes in Haemostasis After Therapeutic Plasmapheresis With Citrate Anticoagulation | A Prospective Interventional Study to Investigate Changes in Haemostasis After Therapeutic Plasmapheresis With Citrate Anticoagulation With or Without Coagulation Factors Replacement | Humoral Rejection;Guillain-Barre Syndrome;Miller Fisher Syndrome;CIDP;Good Pasture Syndrome;Hyperviscosity Syndrome | Drug: Fibrinogen concentrate;Other: Fresh Frozen Plasma | University Medical Centre Ljubljana | NULL | Recruiting | 18 Years | N/A | All | 20 | N/A | Slovenia |
| 12 | NCT02638207 (ClinicalTrials.gov) | September 27, 2017 | 16/12/2015 | Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy | Prospective, Double-blind, Randomized, Multicenter Phase III Study Evaluating Efficacy and Safety of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy | Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy | Drug: NewGam | Octapharma | NULL | Completed | 18 Years | N/A | All | 142 | Phase 3 | Bulgaria;Canada;Czechia;Germany;Hungary;Poland;Romania;Russian Federation;Ukraine;Australia;Denmark;Sweden |
| 13 | NCT03166527 (ClinicalTrials.gov) | June 1, 2017 | 8/5/2017 | Panzyga in CIDP Administered at Different Infusion Rates | Prospective, Open-Label, Phase IIIb Study Evaluating the Safety, Tolerability and Efficacy of Panzyga® in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Administered at Standard and High Infusion Rates | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Drug: Immune Globulin 10% Intravenous Solution | Vera Bril | NULL | Not yet recruiting | 18 Years | N/A | All | 30 | Phase 3 | Canada |
| 14 | NCT02967679 (ClinicalTrials.gov) | December 5, 2016 | 8/11/2016 | SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study | SERENDEM Study: MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study | Chronic Inflammatory Demyelinating Polyneuropathy;Peripheral Neuropathy;Charcot-Marie-Tooth Disease;Charcot-Marie-Tooth Disease Type 1A;Charcot-Marie-Tooth Disease, Type 1B;Anti-MAG Neuropathy | Drug: MD1003 | MedDay Pharmaceuticals SA | NULL | Completed | 20 Years | 85 Years | All | 15 | Phase 2 | France |
| 15 | NCT02885259 (ClinicalTrials.gov) | September 2016 | 25/1/2016 | HyQvia in Multifocal Motor Neuropathy | Subcutaneous Immunoglobulin With rHuPH20 in Multifocal Motor Neuropathy | Multifocal Motor Neuropathy | Drug: rHuPH20 | UMC Utrecht | NULL | Not yet recruiting | 18 Years | 99 Years | Both | 20 | N/A | Netherlands |
| 16 | NCT02556437 (ClinicalTrials.gov) | June 2016 | 18/9/2015 | Efficacy and Safety of HyQvia (Immunoglobulin 10% With Recombinant Hyaluronidase) in Multifocal Motor Neuropathy (MMN) | Randomized, Single-blind, Cross-over Study Investigating the Non-inferiority of Efficacy and Safety of HyQvia in Comparison With Conventional Subcutaneous Ig Therapy in Multifocal Motor Neuropathy | Multifocal Motor Neuropathy | Drug: HyQvia;Drug: Subcuvia | Johannes Jakobsen | Baxter Healthcare Corporation | Completed | 18 Years | 90 Years | All | 18 | Phase 2 | Denmark |
| 17 | NCT02574962 (ClinicalTrials.gov) | August 2015 | 30/8/2015 | Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy | Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy | Chronic Inflammatory Demyelinating Polyneuropathy | Drug: H.P. Acthar® Gel | Mamatha Pasnoor, MD | Mallinckrodt | Withdrawn | 18 Years | N/A | Both | 0 | Phase 2 | United States |
| 18 | NCT02414490 (ClinicalTrials.gov) | March 2015 | 13/3/2015 | IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements | Intravenous Immunoglobulin (IVIg) Treatment-Related Fluctuations in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients Using Daily Grip Strength Measurements (GRIPPER) | Chronic Inflammatory Demyelinating Polyneuropathy | Drug: Intravenous Immunoglobulin | University of Minnesota | BriovaRx Infusion Services;CSL Behring | Completed | 18 Years | 85 Years | All | 30 | United States | |
| 19 | NCT02372149 (ClinicalTrials.gov) | February 2015 | 12/2/2015 | IVIg for Demyelination in Diabetes Mellitus | Treatment With Gamunex 10% Intravenous Immunoglobulin (IVIg) for Patients With Demyelination and Diabetes Mellitus: A Blinded, Placebo-Controlled Crossover Pilot Study | Peripheral Neuropathy;Diabetes Mellitus;Chronic Inflammatory Demyelinating Polyneuropathy | Drug: 10% intravenous immunoglobulin (IVIg);Drug: 0.9% sodium chloride | University of Toronto | University Health Network, Toronto | Recruiting | 18 Years | N/A | Both | 25 | Phase 4 | Canada |
| 20 | NCT02465359 (ClinicalTrials.gov) | September 2014 | 12/12/2014 | Subcutaneous Immunoglobulin for CIDP | A Study of Subcutaneous Immunoglobulin as Chronic Treatment for Patients With Chronic Inflammatory Demyelinating Polyneuropathy | Chronic Inflammatory Demyelinating Polyneuropathy | Drug: Immune Globulin Subcutaneous (Human) | University of South Florida | CSL Behring | Completed | 18 Years | 80 Years | All | 20 | N/A | United States |
| 21 | NCT02111590 (ClinicalTrials.gov) | January 2014 | 9/4/2014 | Immunoglobulin Dosage and Administration Form in CIDP and MMN | The Influence of Immunoglobulin Dosage and Administration on Development of Hemolytic Anemia and Variation on Muscle Strength in Patients With CIDP and MMN | Chronic Inflammatory Demyelinating Polyneuropathy;Multifocal Motor Neuropathy;Hemolytic Anemia | Drug: Immunoglobulins | Rigshospitalet, Denmark | Aarhus University Hospital;Octapharma Pharmazeutika Produktionsges.m.b.H. | Completed | 18 Years | 80 Years | Both | 36 | N/A | Denmark |
| 22 | NCT01951924 (ClinicalTrials.gov) | December 2013 | 20/9/2013 | LIME Study (LFB IVIg MMN Efficacy Study) | A European, Randomised, Double-blind, Active Comparator Controlled, Cross-over, Efficacy and Safety Study of a New 10% Ready To-use Liquid Human Intravenous Immunoglobulin (I10E) Versus Kiovig® in Patients With Multifocal Motor Neuropathy | Motor Neuron Disease | Drug: Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL);Drug: Biological: Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL) | Laboratoire français de Fractionnement et de Biotechnologies | TFS Trial Form Support | Completed | 18 Years | 80 Years | Both | 23 | Phase 3 | France;Italy;Spain;United Kingdom |
| 23 | NCT01827072 (ClinicalTrials.gov) | April 2013 | 1/4/2013 | Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Multifocal Motor Neuropathy. | NPB-01(Intravenous Immunoglobulin) Maintenance Therapy for Patients With Multifocal Motor Neuropathy. | Multifocal Motor Neuropathy | Drug: NPB-01 | Nihon Pharmaceutical Co., Ltd | NULL | Completed | 20 Years | 100 Years | Both | 13 | Phase 3 | Japan |
| 24 | NCT01824251 (ClinicalTrials.gov) | April 2013 | 1/4/2013 | Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. | NPB-01(Intravenous Immunoglobulin) Maintenance Therapy for Patients With Chronic Inflammatory Demyelinating Polyneuropathy. | Chronic Inflammatory Demyelinating Polyneuropathy | Drug: NPB-01 | Nihon Pharmaceutical Co., Ltd | NULL | Completed | 20 Years | 100 Years | Both | 49 | Phase 3 | Japan |
| 25 | NCT00962429 (ClinicalTrials.gov) | February 2009 | 19/8/2009 | Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy | Lipoic Acid for Chronic Inflammatory Demyelinating Polyneuropathy-A Randomized, Double-Blind, Placebo Controlled Pilot Study | CIDP;Chronic Inflammatory Demyelinating Polyneuropathy | Drug: lipoic acid | Oregon Health and Science University | Collins Medical Trust | Completed | 18 Years | 80 Years | All | 7 | Phase 2 | United States |
| 26 | NCT00268788 (ClinicalTrials.gov) | August 2005 | 21/12/2005 | Subcutaneous Immunoglobulin Treatment for Multifocal Motor Neuropathy | A Controlled Cross-Over Trial of Subcutaneous Versus Intravenous Immunoglobulin for Multifocal Motor Neuropathy | Multifocal Motor Neuropathy | Drug: Subcutaneous immunoglobulin;Drug: Intravenous immunoglobulin | University of Aarhus | NULL | Completed | 18 Years | 80 Years | Both | 10 | Phase 2 | Denmark |
| 27 | NCT01349270 (ClinicalTrials.gov) | June 2004 | 5/5/2011 | Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg | Multicentre Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg in Patients With Chronic Inflammatory Demyelinating Polyneuropathy on a One Year Follow up | Demyelinating Polyneuropathy | Drug: Immunoglobulin perfusion;Drug: Prednisone | Centre Hospitalier Universitaire de Saint Etienne | Laboratoire français de Fractionnement et de Biotechnologies | Completed | 18 Years | 80 Years | Both | 40 | Phase 3 | France |
| 28 | NCT00220740 (ClinicalTrials.gov) | April 2004 | 13/9/2005 | Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-Chromatography (IGIV-C), 10% Treatment in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Drug: Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified;Drug: Albumin (Human) 25%, United States Pharmacopeia (USP) | Grifols Therapeutics Inc. | NULL | Completed | 18 Years | N/A | All | 117 | Phase 3 | United States;Argentina;Canada;Czech Republic;Germany;Israel;Italy;Mexico;Poland;Serbia;Former Serbia and Montenegro |
| 29 | NCT01236456 (ClinicalTrials.gov) | October 2003 | 5/11/2010 | High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy | A Phase II Trial of High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy | Chronic Inflammatory Demyelinating Polyneuropathy | Drug: Cyclophosphamide | Stony Brook University | NULL | Withdrawn | 18 Years | 75 Years | All | 0 | Phase 2 | United States |
| 30 | NCT00004772 (ClinicalTrials.gov) | September 1992 | 24/2/2000 | Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Drug: Immune globulin | National Center for Research Resources (NCRR) | Ohio State University | Completed | 15 Years | N/A | Both | 90 | Phase 3 | NULL | |
| 31 | NCT00001287 (ClinicalTrials.gov) | December 1990 | 3/11/1999 | Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | The Efficacy of High-Dose Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Demyelinating Diseases;Paraproteinemias | Drug: intravenous immunoglobulin (IVIg) | National Institute of Neurological Disorders and Stroke (NINDS) | NULL | Completed | N/A | N/A | Both | 60 | Phase 2 | United States |